Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial-Reference-Cited by-同舟云学术

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

Published:2010-11 Issue:11 Volume:11 Page:1029-1035
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Mahon François-Xavier,Réa Delphine,Guilhot Joëlle,Guilhot François,Huguet Françoise,Nicolini Franck,Legros Laurence,Charbonnier Aude,Guerci Agnès,Varet Bruno,Etienne Gabriel,Reiffers Josy,Rousselot Philippe

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia;Druker;N Engl J Med,2001

2. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia;Kantarjian;N Engl J Med,2002

3. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med,2003

4. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

5. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib;Deininger;Blood,2009

Cited by 1301 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial;The Lancet Oncology;2024-09

2. DEEP MOLECULAR RESPONSE RATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: ELEGIBILITY TO DISCONTINUATION RELATED TO TIME TO RESPONSE AND DIFFERENT FRONTLINE TKI IN THE EXPERIENCE OF THE GIMEMA LABNET CML NATIONAL NETWORK;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Dynamics and bifurcations in a model of chronic myeloid leukemia with optimal immune response windows;Journal of Mathematical Biology;2024-08-23

4. Comparative analysis of BCR::ABL1 p210 mRNA transcript quantification and ratio to ABL1 control gene converted to the International Scale by chip digital PCR and droplet digital PCR for monitoring patients with chronic myeloid leukemia;Clinical Chemistry and Laboratory Medicine (CCLM);2024-08-20

5. The frequency of cardiovascular events caused by second-generation tyrosine kinase inhibitors may depend on the treatment intensity in patients with chronic myeloid leukemia;2024-08-18